Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
undruggable targets
Biotech
Terremoto takes $108M series C to fuel trials of AKT1 inhibitors
Terremoto has spelt out how the California biotech will use a $108 million round to continue its efforts to broaden the covalent drug alphabet.
James Waldron
Apr 15, 2026 7:43am
Novartis finds natural partnership in macrocycle biotech
Feb 18, 2026 10:13am
Argenx's $1.5B pact to turn macrocyclic peptides to new targets
Jul 1, 2025 8:00am
GPCR firm Septerna files for IPO on strength of preclinical data
Oct 3, 2024 6:00am
AACR: KRAS inhibitors pop in preclinical data debuts
Apr 11, 2024 4:30am
Lilly inks backloaded $660M Prism drug discovery pact
Nov 29, 2023 5:53am
